Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNYSE:JNJNYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$185.52+1.8%$186.21$163.52▼$218.66$327.70B0.56.24 million shs3.25 million shsJNJJohnson & Johnson$152.18-0.2%$153.75$140.68▼$169.99$366.16B0.428.01 million shs4.32 million shsMRKMerck & Co., Inc.$79.02-0.1%$79.06$73.31▼$129.93$198.42B0.3813.14 million shs7.48 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%-1.77%-1.96%-13.32%+6.04%JNJJohnson & Johnson0.00%+1.76%-1.65%-8.11%+4.30%MRKMerck & Co., Inc.0.00%-0.40%+2.69%-12.05%-36.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.9534 of 5 stars3.45.04.23.92.92.51.3JNJJohnson & Johnson4.9571 of 5 stars3.35.04.23.93.01.71.9MRKMerck & Co., Inc.4.997 of 5 stars3.23.05.03.93.02.53.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.81Moderate Buy$211.2913.89% UpsideJNJJohnson & Johnson 2.55Moderate Buy$170.8812.29% UpsideMRKMerck & Co., Inc. 2.43Hold$109.1938.18% UpsideCurrent Analyst Ratings BreakdownLatest MRK, JNJ, and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$205.006/9/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$204.006/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.005/20/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Cautious5/14/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$210.00 ➝ $205.005/14/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$115.00 ➝ $84.005/13/2025JNJJohnson & JohnsonLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025JNJJohnson & JohnsonLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.005/8/2025ABBVAbbVieBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/29/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$214.00 ➝ $216.004/28/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B5.82$15.19 per share12.21$1.90 per share97.64JNJJohnson & Johnson$88.82B4.12$13.10 per share11.62$29.69 per share5.13MRKMerck & Co., Inc.$63.92B3.10$9.45 per share8.36$18.33 per share4.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3578.9513.271.217.31%412.03%13.11%7/24/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9916.9313.752.3124.42%33.46%13.30%7/16/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.8711.507.980.8227.27%43.23%17.11%7/29/2025 (Estimated)Latest MRK, JNJ, and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025ABBVAbbVie$3.24N/AN/AN/A$14.93 billionN/A7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion4/24/2025Q1 2025MRKMerck & Co., Inc.$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.54%N/A279.15%53 YearsJNJJohnson & Johnson$5.203.42%N/A57.84%64 YearsMRKMerck & Co., Inc.$3.244.10%N/A47.16%14 YearsLatest MRK, JNJ, and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/20255/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/20254/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.760.64JNJJohnson & Johnson0.491.261.03MRKMerck & Co., Inc.0.691.411.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%JNJJohnson & Johnson0.16%MRKMerck & Co., Inc.0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableMRKMerck & Co., Inc.75,0002.51 billion2.51 billionOptionableMRK, JNJ, and ABBV HeadlinesRecent News About These Companies7,162 Shares in Merck & Co., Inc. (NYSE:MRK) Bought by G&S Capital LLCJune 30 at 9:17 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Sold by Essex LLCJune 30 at 9:16 AM | marketbeat.comRed Door Wealth Management LLC Acquires 8,717 Shares of Merck & Co., Inc. (NYSE:MRK)June 30 at 8:55 AM | marketbeat.comInsight Inv LLC Buys 14,987 Shares of Merck & Co., Inc. (NYSE:MRK)June 30 at 8:18 AM | marketbeat.comArgent Advisors Inc. Acquires 4,029 Shares of Merck & Co., Inc. (NYSE:MRK)June 30 at 7:58 AM | marketbeat.comRed Cedar Investment Management LLC Sells 10,004 Shares of Merck & Co., Inc. (NYSE:MRK)June 30 at 7:50 AM | marketbeat.comCanandaigua National Bank & Trust Co. Raises Stake in Merck & Co., Inc. (NYSE:MRK)June 30 at 7:49 AM | marketbeat.comValley National Advisers Inc. Has $1.77 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)June 30 at 7:48 AM | marketbeat.comNew York State Teachers Retirement System Sells 93,982 Shares of Merck & Co., Inc. (NYSE:MRK)June 30 at 6:40 AM | marketbeat.comAlbion Financial Group UT Decreases Stock Position in Merck & Co., Inc. (NYSE:MRK)June 30 at 6:33 AM | marketbeat.comAmalgamated Bank Purchases 13,211 Shares of Merck & Co., Inc. (NYSE:MRK)June 30 at 6:22 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) is Augustine Asset Management Inc.'s 10th Largest PositionJune 29 at 7:39 AM | marketbeat.comStonebridge Financial Group LLC Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK)June 29 at 7:15 AM | marketbeat.comKBC Group NV Sells 227,229 Shares of Merck & Co., Inc. (NYSE:MRK)June 29 at 7:06 AM | marketbeat.comCFM Wealth Partners LLC Sells 3,699 Shares of Merck & Co., Inc. (NYSE:MRK)June 29 at 5:49 AM | marketbeat.comColonial River Investments LLC Cuts Stock Position in Merck & Co., Inc. (NYSE:MRK)June 29 at 5:49 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Sold by Allspring Global Investments Holdings LLCJune 29 at 5:32 AM | marketbeat.comMerck: Don't Let Today's Bargain Opportunity Pass You ByJune 29 at 4:00 AM | seekingalpha.comMerck & Co., Inc. (NYSE:MRK) Shares Acquired by Sumitomo Mitsui Trust Group Inc.June 28 at 8:04 AM | marketbeat.comMarathon Asset Management Ltd Sells 31,751 Shares of Merck & Co., Inc. (NYSE:MRK)June 28 at 7:32 AM | marketbeat.comHighland Capital Management LLC Sells 16,560 Shares of Merck & Co., Inc. (NYSE:MRK)June 28 at 6:39 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK, JNJ, and ABBV Company DescriptionsAbbVie NYSE:ABBV$185.52 +3.21 (+1.76%) As of 03:41 PM EasternAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$152.18 -0.23 (-0.15%) As of 03:41 PM EasternJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Merck & Co., Inc. NYSE:MRK$79.02 -0.08 (-0.10%) As of 03:41 PM EasternMerck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
